Open Access
Access granted
Subscription or Fee Access
No 3 (2009)
- Year: 2009
- Articles: 14
- URL: https://journals.eco-vector.com/2075-3594/issue/view/6290
Articles
5-7
8-13
Urinary angiotensinogen concentration as a novel marker of cardio-renal syndrome
Abstract
Urinary angiotensinogen concentration adequately reflects the activity of the kidney pool of renin-angiotensin-aldosterone system (RAAS). Experimental and clinical studies allow considering this indicant as a reliable early marker of cardio-renal syndrome, reflecting the formation and progression of kidney damage and characterizing the effectiveness of RAAS blockers
Clinical nephrology. 2009;(3):14-18
14-18
19-22
Genetic thrombophylia and kidney
Abstract
Thrombophilia is defined as predisposition of the organism to thrombosis development. There are acquired and inherited thrombophilia; both of them are considered as risk factors for arterial, venous and microcirculatory thrombosis. Kidney disease in patients with a genetic polymorphism of coagulation factors are manifested as renal vein and artery thrombosis, and thrombosis of renal microvasculature - thrombotic microangiopathy. Combination of thrombotic microangiopathy and chronic glomerulonephritis further the disease progression due to progressive nephrosclerosis
Clinical nephrology. 2009;(3):23-34
23-34
35-42
Pericarditis in chronic renal failure
Abstract
We discuss the approaches to the differential diagnosis and management of pericarditis, which occur in patients with chronic renal insufficiency, including patients treated with programmed hemodialysis. Mechanisms of the genesis and principles of treatment of cardiac tamponade are particularized
Clinical nephrology. 2009;(3):43-46
43-46
Associated kidney and liver diseases in children
Abstract
The approaches to diagnosis and treatment of combined liver and kidney diseases in children such as HBV- and HCV-associated glomerulonephritis, autosomal-recessive kidney disease, glycogen storage disease, Wilson's disease, and hepato-renal syndrome are presented
Clinical nephrology. 2009;(3):47-51
47-51
Primenenie preparatov eritropoetina u bol'nykh terminal'noy pochechnoy nedostatochnost'yu, nakhodyashchikhsya na programmnom gemodialize (rezul'taty mul'titsentrovogo observatsionnogo issledovaniya)
Abstract
Purpose. Evaluation of efficacy and safety of EPO drug in patients treated with programmed hemodialysis in real clinical practice in Russia.
Material and methods. Observational, noninterventional study include 431 patients with terminal renal insufficiency treated with programmed hemodialysis for at least 12 months and regularly received EPO drug. The study was conducted in 11 hemodialysis centers. We have assessed the adequacy of management of patients and the adverse events rates.
Results. 49.9% of patients received Recormon, 36.7% - Eprex, 9.0% - Epocrin, and 4.4% of patients - Eralfon. When comparison of hemodialysis centers, we have observed significant differences in the survey protocol and management of patients, leading to reduction of efficacy of EPO drug. Correction of hemoglobin was used only in 21.2% of patients; 78.8% of patients received erythropoietin on conventional regimen. At a time when correction was used, target level of hemoglobin was achieved in 69% of patients. In contrast, target level of hemoglobin was achieved in 31% of patients only with "routine" administration of EPO drugs. Periods of achieving of target level of hemoglobin against the background of correction use were 3 times shorter compared with its absence.
Conclusion. The actual practice of use of EPO drugs in patients treated with programmed hemodialysis requires further optimization.
Clinical nephrology. 2009;(3):52-56
52-56
Albuminuria, plasma endothelin-1 and carotid atherosclerosis in patients with arterial hypertension and hyperuricemia
Abstract
Purpose. Evaluation of associations between hyperuricaemia, endothelial dysfunction markers, and atherosclerotic carotid arteries in patients with arterial hypertension.
Material and methods. The study included 40 patients with essential arterial hypertension of I-II-degree without associated clinical conditions, type 2 diabetes mellitus and metabolic syndrome. Thirty patients with hyperuricemia were enrolled in basic group, and 10 patients with normal concentration of uric acid were enrolled in the control group.
Results. Compared with patients with normal serum uric acid level, albuminuria (91.4 ± 1.9 vs 60.7 ± 2.2 mg/l, p <0.001), plasma concentrations of endothelin -1 (6.7 ± 0.1 vs 4.9 ± 0.2 pg/ml, p<0.001) and the thickness of the intima-media of the common carotid artery (IMT CCA) (1.3 ± 0.02 vs 1.1 ± 0.04 mm, p <0.001) were significantly increased in the group of hypertensive patients with hyperuricaemia. Reliable direct correlations between uricemia, albuminuria, plasma concentrations of endothelin-1, and IMT CCA have been found.
Conclusion. The significant increase in endothelial dysfunction markers (albuminuria, plasma concentrations of endothelin-1) and IMT CCA pathogenetically related to persistent increase of uric acid in blood serum in hypertensive patients with hyperuricaemia was found.
Clinical nephrology. 2009;(3):57-61
57-61
Can we manage arterial hypertension without hydrochlorothiazide?
Abstract
Currently we have accumulated considerable experience of hydrochlorothiazide use in hypertensive patients justifying substantially decrease of risk of cardiovascular complications. The article discusses clinical studies confirming the advisability of hydrochlorothiazide use in patients with hypertension, as well as ways to prevent adverse events associated with its use, including type 2 diabetes mellitus
Clinical nephrology. 2009;(3):62-67
62-67
Multiple renal arteries as a cause of resistant arterial hypertension
Abstract
The significance of multiple (double, triple) renal arteries in the development of resistant hypertension is discussed, and approaches to the differential diagnosis of this anatomical anomaly with different types of renovascular hypertension are presented
Clinical nephrology. 2009;(3):68-72
68-72
73-78
Acute diffuse nephritis (60th anniversary of publishing).
Clinical nephrology. 2009;(3):79-79
79-79